✦ LIBER ✦

PCV11 ASSESSMENT AND QUANTIFICATION OF THE BENEFIT RISK RATIO OF ROSUVASTATIN AND ATORVASTATIN FROM A META-ANALYSIS OF HEAD TO HEAD RANDOMISED CONTROLLED TRIALS

✍ Scribed by JH Wlodarczyk; M Smith; DR Sullivan

Book ID: 118609293
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 92 KB
Volume: 11
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)70599-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparative Harm-Benefits of Rosuvastati

Comparative Harm-Benefits of Rosuvastatin and Atorvastatin—Meta Analysis of Head to Head Randomised Controlled Clinical Trials

✍ D. Sullivan; J. Wlodarczyk; M. Smith 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Comparison of Benefits and Risks of Rosu

Comparison of Benefits and Risks of Rosuvastatin Versus Atorvastatin from a Meta-Analysis of Head-to-Head Randomized Controlled Trials

✍ John Wlodarczyk; David Sullivan; Michael Smith 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 963 KB

PCV6 ESTIMATING THE INCREMENTAL BENEFIT

PCV6 ESTIMATING THE INCREMENTAL BENEFIT ON FINAL OUTCOMES OF ROSUVASTATIN 40 MG OVER 20 MG IN THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLAEMIA BASED ON A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

✍ SL Kingslake; SJ Edwards 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Donepezil for the symptomatic treatment

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

✍ Anne Whitehead; Carlos Perdomo; Raymond D. Pratt; Jacqueline Birks; Gordon K. Wi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 3 views

## Abstract ## Background The objective was to evaluate the efficacy and tolerability of donepezil (5 and 10 mg/day) compared with placebo in alleviating manifestations of mild to moderate Alzheimer's disease (AD). ## Method A systematic review of individual patient data from Phase II and III do

Review finds primary stenting lowers the

Review finds primary stenting lowers the risk of reinfarction and revascularisation, but does not improve survival compared to balloon angioplasty: Abstracted from: Nordmann AJ, Hengstler P, Harr T, et al. Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. Am J Med. 2004; 116: 253–62.

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 127 KB